OUR portfolio

Our investments accelerate growth and stimulate private sector innovation and investment.

Filter by:
  • 1mg

    Online-to-offline healthcare services in India

    Focus areas
    Healthcare Delivery
    Investment type
    Direct equity
    Status
    Exit
    1mg

    Online-to-offline healthcare services in India

    1mg Technologies Private Limited, a digital consumer healthcare platform in India, provides online-to-offline services to help customers access medicines, diagnostics, and tele-consultations. The foundation’s investment accelerated the low-cost delivery of high-quality essential medicines and other healthcare services across India’s underserved regions.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Series E
    Partnered in
    2020
    Headquarters
    India
  • Abbott

    Expanded rapid COVID-19 testing in LMICs

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Abbott

    Expanded rapid COVID-19 testing in LMICs

    Abbott Laboratories received the foundation’s support to enable the distribution of its Panbio COVID-19 Ag Rapid Test in low- and middle-income countries. The availability of rapid diagnostic tests that are both cost-effective and produce results within 15–20 minutes is critical in combating the spread of the pandemic.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2020
    Headquarters
    USA
  • Aurobindo: Committed to healthier life

    Expanded LMIC access to single-pill HIV treatment

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Aurobindo: Committed to healthier life

    Expanded LMIC access to single-pill HIV treatment

    Aurobindo Pharma, along with Mylan Laboratories, received support from the foundation to expand the low-price distribution to low- and middle-income populations of a single-pill HIV treatment containing dolutegravir.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2017
    Headquarters
    India
  • BASF: We create chemistry

    Expanded LMIC access to next-generation malaria bednets

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    BASF: We create chemistry

    Expanded LMIC access to next-generation malaria bednets

    Volume guarantee to accelerate adoption of next-generation, dual AI bednets to protect against malaria.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2019
    Headquarters
    Germany
  • Bayer

    Expanded LMIC access to long-acting, reversible contraceptive implant

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Bayer

    Expanded LMIC access to long-acting, reversible contraceptive implant

    Bayer, along with private and public organizations, partnered with the foundation to make Jadelle®—an effective, long-acting, reversible contraceptive implant—available to more than 27 million women in the world’s poorest countries at a more than 50 percent price reduction.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2013
    Headquarters
    Germany
  • BioFarma

    Expanded LMIC access to novel oral poliovirus vaccine

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    BioFarma

    Expanded LMIC access to novel oral poliovirus vaccine

    BioFarma received foundation support to expand access to its novel oral poliovirus vaccine type 2 (nOPV2) for the Global Polio Eradication Initiative.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Private
    Partnered in
    2022
    Headquarters
    Indonesia
  • Biological E. Limited: Celebrating life every day

    Reduced vaccine production cost

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Biological E. Limited: Celebrating life every day

    Reduced vaccine production cost

    Biological E, a pharmaceutical company, identifies innovative approaches to reduce the cost of vaccine production.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Private
    Partnered in
    2012
    Headquarters
    India
  • Clinton Health Access Initiative

    Reduced pricing for lifesaving commodities

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Clinton Health Access Initiative

    Reduced pricing for lifesaving commodities

    The Clinton Health Access Initiative received a guarantee from the foundation to structure volume guarantees that reduce the price and increase access to lifesaving commodities in the developing world.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Private
    Partnered in
    2015
    Headquarters
    USA
  • DKT International

    Safe, affordable contraceptives in developing countries

    Focus areas
    Healthcare Delivery
    Investment type
    Debt
    Status
    Exit
    DKT International

    Safe, affordable contraceptives in developing countries

    DKT International is increasing sustainable access to vital reproductive health products in developing countries, where many people lack access to safe and affordable contraceptives.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Debt
    Status
    Exit
    Initial investment
    NGO
    Partnered in
    2016
    Headquarters
    USA
  • Dr Reddys Laboratories Molnupiravir

    Ensured LMIC access to molnupiravir

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Dr Reddys Laboratories Molnupiravir

    Ensured LMIC access to molnupiravir

    Dr. Reddys Laboratories, a multinational pharmaceutical company, is expanding access to generic molnupiravir in low- and middle-income countries.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2022
    Headquarters
    India